Edition:
United Kingdom

Vanda Pharmaceuticals Inc (VNDA.OQ)

VNDA.OQ on NASDAQ Stock Exchange Global Market

14.43USD
7:09pm GMT
Change (% chg)

$0.08 (+0.52%)
Prev Close
$14.35
Open
$14.50
Day's High
$14.55
Day's Low
$14.30
Volume
28,214
Avg. Vol
159,772
52-wk High
$18.95
52-wk Low
$11.90

Chart for

About

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment... (more)

Overall

Beta: 1.37
Market Cap(Mil.): $778.29
Shares Outstanding(Mil.): 44.86
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Vanda receives negative opinion for marketing authorization from the European Medicines Agency

* Vanda receives negative opinion for marketing authorization from the European Medicines Agency on fanaptum™ for the treatment of schizophrenia

10 Nov 2017

BRIEF-Vanda Pharmaceuticals posts qtrly ‍net loss of $0.10​/share

* Qtrly ‍net loss per share $0.10​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

07 Nov 2017

BRIEF-Vanda Pharmaceuticals reached a pricing agreement with the German National Association of Statutory Health Insurance Funds

* Vanda Pharmaceuticals - On Oct 17, co reached a pricing agreement with the German National Association of Statutory Health Insurance Funds

18 Oct 2017

BRIEF-Vanda Pharmaceutical ‍announced results from study of Tradipitant as a treatment of chronic pruritus

* Vanda Pharmaceuticals Inc - ‍announced results from randomized phase ii clinical study of Tradipitant as a monotherapy in treatment of chronic pruritus

13 Sep 2017

BRIEF-Vanda Pharmaceuticals qtrly ‍net loss per share $0.03​

* Vanda Pharmaceuticals Inc - ‍total net product sales were $42.1 million in Q2 of 2017​

02 Aug 2017

BRIEF-Vanda receives negative opinion for marketing authorization from the EMA on Fanaptum

* Vanda receives negative opinion for marketing authorization from the European Medicines Agency on Fanaptum™ for the treatment of schizophrenia

21 Jul 2017

BRIEF-Armistice Capital Llc reports 5.1 pct passive stake in Vanda Pharmaceuticals Inc

* Armistice Capital Llc reports a 5.1 percent passive stake in Vanda Pharmaceuticals Inc as of June 7 - sec filing Source text for Eikon: (http://bit.ly/2rwELbT) Further company coverage:

19 Jun 2017

Competitors

Earnings vs. Estimates